|
시장보고서
상품코드
1727674
세계의 항체-올리고뉴클레오티드 접합체(AOC) 시장 : 예측(-2031년)Global Antibody-oligonucleotide Conjugates (AOCs) Market Insights, Forecast to 2031 |
||||||
QYResearch
세계 항체-올리고뉴클레오티드 접합체(AOC) 시장 규모는 2026년 312만 달러에서 2031년에는 2억 9,141만 달러에 달할 것으로 예상되며, 예측 기간(2026-2031년) 동안 연평균 성장률(CAGR)은 147.78%에 달할 것으로 예상됩니다.
미국과 캐나다의 항체-올리고뉴클레오티드 접합체(AOC) 시장 규모는 2026년 204만 달러에서 2031년에는 1억 6,503만 달러에 달할 것으로 예상되며, 예측 기간(2026-2031년) 동안 연평균 140.81%의 CAGR을 기록할 것으로 예상됩니다.
유럽의 항체-올리고뉴클레오티드 접합체(AOC) 시장 규모는 2026년 108만 달러에서 2031년에는 9,695만 달러에 달할 것으로 예상되며, 2026년부터 2031년까지 예측 기간 동안 연평균 145.73%의 CAGR을 기록할 것으로 예상됩니다.
Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio, Denali Therapeutics 등 세계 주요 항체-올리고뉴클레오티드 접합체(AOC) 업체들이 있습니다. AOC 분야에서 기술 혁신이 진행됨에 따라 경쟁도 점차 심화되고 있습니다. 특히 암과 신경퇴행성 질환 분야에서는 대형 기업들의 신약 후보물질 출시가 이어지고 있어 시장 경쟁은 더욱 치열해질 것으로 보입니다.
보고서 내용
항체-올리고뉴클레오티드 접합체(AOC) 세계 시장 규모를 개관합니다. 세계 시장 동향을 분석하고, 2020-2024년의 과거 시장 수익 데이터, 2024년 추정 및 예측, 2031년까지의 CAGR 예측을 게재하고 있습니다.
항체-올리고뉴클레오티드 접합체(AOC)의 주요 생산자 및 주요 지역/국가별 매출을 조사했습니다. 항체-올리고뉴클레오티드 접합체(AOC)의 향후 시장 잠재력의 주요 하이라이트와 주요 지역/국가에 초점을 맞추어 이 시장을 다양한 부문 및 하위 부문으로 예측합니다. 미국, 캐나다, 멕시코, 브라질, 중국, 일본, 한국, 동남아시아, 인도, 독일, 영국, 이탈리아, 중동 및 아프리카, 기타 국가들의 국가별 데이터와 시장 가치 분석을 정리했습니다.
이 보고서는 2020년부터 2024년까지 항체-올리고뉴클레오티드 접합체(AOC) 매출, 시장 점유율, 주요 기업의 업계 순위에 초점을 맞춘 2020년부터 2024년까지의 데이터를 제공합니다. 세계 항체-올리고뉴클레오티드 접합체(AOC) 시장의 주요 이해관계자를 파악하고, 최근 동향과 부문별 매출에 기반한 경쟁 환경과 시장 지위를 분석합니다. 이 보고서는 이해관계자들이 경쟁 상황을 이해하고 더 깊은 인사이트를 얻어 사업 및 시장 전략을 보다 잘 수립할 수 있도록 도와줍니다.
이 보고서는 2020년부터 2031년까지 유형별, 용도별, 지역별 부문 데이터, 수익, 성장률에 대해 분석합니다. 항체-올리고뉴클레오티드 접합체(AOC)의 수익, 예측 성장 동향, 생산 기술, 용도, 최종사용자 산업의 시장 규모를 평가하고 예측합니다.
목차
제1장 보고서 개요
- 조사 범위
- 유형별 시장 분석
- 용도별 시장
- 가정과 제한
- 조사 목적
- 대상 연도
제2장 세계의 경제 성장 동향
- 세계의 항체-올리고뉴클레오티드 접합체(AOC) 시장 전망(2020-2031년)
- 세계의 항체-올리고뉴클레오티드 접합체(AOC) 성장 동향, 지역별
- 항체-올리고뉴클레오티드 접합체(AOC) 시장 역학
제3장 주요 진출 기업에 의한 경쟁 구도
제4장 항체-올리고뉴클레오티드 접합체(AOC) 내역 데이터, 유형별
- 세계의 항체-올리고뉴클레오티드 접합체(AOC) 시장 규모 실적, 유형별(2020-2025년)
- 세계의 항체-올리고뉴클레오티드 접합체(AOC) 시장 규모 예측, 유형별(2026-2031년)
제5장 항체-올리고뉴클레오티드 접합체(AOC) 내역 데이터, 용도별
- 세계의 항체-올리고뉴클레오티드 접합체(AOC) 시장 규모 실적, 용도별(2020-2025년)
- 세계의 항체-올리고뉴클레오티드 접합체(AOC) 시장 규모 예측, 용도별(2026-2031년)
제6장 북미
제7장 유럽
제8장 중국
제9장 아시아(중국 제외)
제10장 중동 및 아프리카, 라틴아메리카
제11장 주요 기업 개요
- Avidity Biosciences
- Dyne Therapeutics
- Tallac Therapeutics
- Denali Therapeutics
- Gennao Bio
- ChainGen Bio
제12장 산업 체인과 판매 채널 분석
- 항체-올리고뉴클레오티드 접합체(AOC) 산업 체인 분석
- 항체-올리고뉴클레오티드 접합체(AOC)의 주요 원재료
- 항체-올리고뉴클레오티드 접합체(AOC) 판매 및 마케팅
- 항체-올리고뉴클레오티드 접합체(AOC) 고객
제13장 애널리스트의 관점/결론
제14장 부록
ksm 25.06.04The global Antibody-oligonucleotide Conjugates (AOCs) market is projected to grow from US$ 3.12 million in 2026 to US$ 291.41 million by 2031, at a Compound Annual Growth Rate (CAGR) of 147.78% during the forecast period (2026-2031).
The US & Canada market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 2.04 million in 2026 to reach $ 165.03 million by 2031, at a CAGR of 140.81% during the forecast period of 2026 through 2031.
The Europe market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 1.08 million in 2026 to reach $ 96.95 million by 2031, at a CAGR of 145.73% during the forecast period of 2026 through 2031.
The global key companies of Antibody-oligonucleotide Conjugates (AOCs) include Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc. As innovations continue to emerge in the field of AOCs, competition is also gradually intensifying. Major companies continue to launch new drug candidates, especially in the fields of cancer and neurodegenerative diseases, and the competition for market share will become more intense.
Report Includes
This report presents an overview of global market for Antibody-oligonucleotide Conjugates (AOCs) market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2024, and projections of CAGR through 2031.
This report researches the key producers of Antibody-oligonucleotide Conjugates (AOCs), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody-oligonucleotide Conjugates (AOCs), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Antibody-oligonucleotide Conjugates (AOCs) revenue, market share and industry ranking of main companies, data from 2020 to 2024. Identification of the major stakeholders in the global Antibody-oligonucleotide Conjugates (AOCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Antibody-oligonucleotide Conjugates (AOCs) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc.
Market Segmentation
By Company
- Avidity Biosciences
- Dyne Therapeutics
- Tallac Therapeutics
- Denali Therapeutics
- Gennao Bio
- ChainGen Bio
Segment by Type
- Site-specific Conjugation
Random Conjugation
- Segment by Application
- Rare and Genetic Diseases
- Cancer Treatment
- Central Nervous System Disorders
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Antibody-oligonucleotide Conjugates (AOCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-oligonucleotide Conjugates (AOCs) revenue, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials and customers.
Chapter 13: Analyst's Viewpoints/Conclusions
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type: 2026 VS 2031
- 1.2.2 Site-specific Conjugation
- 1.2.3 Random Conjugation
- 1.3 Market by Application
- 1.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2026 VS 2031
- 1.3.2 Rare and Genetic Diseases
- 1.3.3 Cancer Treatment
- 1.3.4 Central Nervous System Disorders
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Perspective (2020-2031)
- 2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Growth Trends by Region
- 2.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2026 VS 2031
- 2.2.2 Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Region (2020-2025)
- 2.2.3 Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031)
- 2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Dynamics
- 2.3.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends
- 2.3.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
- 2.3.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
- 2.3.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Revenue Antibody-oligonucleotide Conjugates (AOCs) by Players
- 3.1.1 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025)
- 3.1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Players (2020-2025)
- 3.2 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs) Head office and Area Served
- 3.3 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
- 3.4 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Type
- 4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Type (2020-2025)
- 4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031)
5 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Application
- 5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Application (2020-2025)
- 5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031)
6 North America
- 6.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
- 6.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
- 6.2.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
- 6.2.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
- 6.2.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
- 6.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
- 6.3.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
- 6.3.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
- 6.3.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
- 6.4 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
- 6.4.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
- 6.4.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
- 6.4.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)
- 6.4.4 United States
- 6.4.5 Canada
7 Europe
- 7.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
- 7.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
- 7.2.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
- 7.2.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
- 7.2.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
- 7.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
- 7.3.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
- 7.3.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
- 7.3.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
- 7.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
- 7.4.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
- 7.4.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
- 7.4.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
- 7.4.4 Germany
- 7.4.5 France
- 7.4.6 U.K.
- 7.4.7 Italy
- 7.4.8 Russia
8 China
- 8.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
- 8.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
- 8.2.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
- 8.2.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
- 8.2.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2027-2031)
- 8.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
- 8.3.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
- 8.3.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
- 8.3.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)
9 Asia (excluding China)
- 9.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
- 9.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
- 9.2.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
- 9.2.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
- 9.2.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
- 9.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
- 9.3.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
- 9.3.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
- 9.3.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)
- 9.4 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region
- 9.4.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2027 VS 2031
- 9.4.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025)
- 9.4.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031)
- 9.4.4 Japan
- 9.4.5 South Korea
- 9.4.6 Southeast Asia
- 9.4.7 India
- 9.4.8 Australia
10 Middle East, Africa, and Latin America
- 10.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
- 10.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
- 10.2.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
- 10.2.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
- 10.2.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
- 10.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
- 10.3.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
- 10.3.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
- 10.3.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2020-2031)
- 10.4 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
- 10.4.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
- 10.4.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
- 10.4.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
- 10.4.4 Mexico
- 10.4.5 Brazil
- 10.4.6 Middle East & Africa
11 Key Players Profiles
- 11.1 Avidity Biosciences
- 11.1.1 Avidity Biosciences Company Details
- 11.1.2 Avidity Biosciences Business Overview
- 11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Introduction
- 11.1.4 Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business 2026 VS 2031
- 11.1.5 Avidity Biosciences Recent Development
- 11.2 Dyne Therapeutics
- 11.2.1 Dyne Therapeutics Company Details
- 11.2.2 Dyne Therapeutics Business Overview
- 11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
- 11.2.4 Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
- 11.2.5 Dyne Therapeutics Recent Development
- 11.3 Tallac Therapeutics
- 11.3.1 Tallac Therapeutics Company Details
- 11.3.2 Tallac Therapeutics Business Overview
- 11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
- 11.3.4 Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
- 11.3.5 Tallac Therapeutics Recent Development
- 11.4 Denali Therapeutics
- 11.4.1 Denali Therapeutics Company Details
- 11.4.2 Denali Therapeutics Business Overview
- 11.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
- 11.4.4 Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
- 11.4.5 Denali Therapeutics Recent Development
- 11.5 Gennao Bio
- 11.5.1 Gennao Bio Company Details
- 11.5.2 Gennao Bio Business Overview
- 11.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction
- 11.5.4 Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
- 11.6 ChainGen Bio
- 11.6.1 ChainGen Bio Company Details
- 11.6.2 ChainGen Bio Business Overview
- 11.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction
- 11.6.4 ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
12 Industry Chain and Sales Channels Analysis
- 12.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Chain Analysis
- 12.2 Antibody-oligonucleotide Conjugates (AOCs) Key Raw Materials
- 12.2.1 Key Raw Materials
- 12.2.2 Raw Materials Key Suppliers
- 12.3 Antibody-oligonucleotide Conjugates (AOCs) Sales and Marketing
- 12.4 Antibody-oligonucleotide Conjugates (AOCs) Customers
13 Analyst's Viewpoints/Conclusions
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.2 Data Source
- 14.2 Author Details
- 14.3 Disclaimer 97
